抗体プロテオミクス技術による新規治療標的候補の同定と分子標的治療薬開発への挑戦

  • 長野 一也
    大阪大学大学院薬学研究科・毒性学分野 国立研究開発法人医薬基盤・健康・栄養研究所

書誌事項

タイトル別名
  • Challenge to the Development of Molecular Targeted Therapy against a Novel Target Candidate Identified by Antibody Proteomics Technology
  • Symposium Review 抗体プロテオミクス技術による新規治療標的候補の同定と分子標的治療薬開発への挑戦
  • Symposium Review コウタイ プロテオミクス ギジュツ ニ ヨル シンキ チリョウ ヒョウテキ コウホ ノ ドウテイ ト ブンシ ヒョウテキ チリョウヤク カイハツ エ ノ チョウセン

この論文をさがす

抄録

  Disease proteomics that systemically analyzes and identifies differentially expressed proteins between healthy and diseased samples is a potentially useful approach for obtaining target proteins for drug development. To date, however, very few target proteins have been identified from this field. A key issue that remains to be resolved is how to correctly identify target proteins from a number of potential candidates. To circumvent this problem, we have developed “antibody proteomics technology” in which a single chain Fv phage antibody library is utilized for proteome analysis. Here, we describe the application of this technology by primarily focusing on Eph receptor A10 (EphA10), a novel breast cancer-related protein that is a promising target for antibody drugs. To establish an effective and safe targeted cancer therapy, it is important that the target is specifically expressed in cancer tissues. Therefore, we attempted to analyze the EphA10 expression profiles. Tissue microarray analysis showed that EphA10 was expressed in all subtypes of breast cancer containing triple negative breast cancer cases. On the other hand, EphA10 was only expressed in testis tissue among 36 kinds of normal tissues. Thus, EphA10 could be a highly cancer-specific protein, making it a promising target for female breast cancer patients. Finally, we examined the anti-tumor effect by anti-EphA10 antibody, aiming for the development of a novel EphA10 targeting therapy. Administration of the antibody showed that tumor volumes were significantly inhibited. Our results suggest that targeting EphA10 in breast cancer cases might be a promising new form of therapy.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 136 (2), 145-149, 2016-02-01

    公益社団法人 日本薬学会

参考文献 (11)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ